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Purpose: Branch retinal vein occlusion (BRVO) is a common vision-threatening disease. Compression of the underlying
retinal vein due to increased rigidity of the crossing artery has been implicated in the pathogenesis of BRVO. Among
others, arterial hypertension and hypercholesterolemia, both of which contribute to atherogenesis, have been identified as
risk factors. Atherosclerosis itself is a chronic low-grade inflammatory disease with a distinct pro-inflammatory cytokine
pattern. In addition to their role in atherogenesis, some cytokines have been shown to exert procoagulatory effects, and
may thus contribute to the development of BRVO by a second mechanism. Gene polymorphisms affecting the expression
of inflammation-related cytokines are therefore candidates as potential risk factors for BRVO. The purpose of the present
study was to investigate hypothesized associations between cytokine gene polymorphisms and the presence of BRVO.
Methods: The study comprised 398 patients with BRVO and 355 control subjects. Using 5′exonuclease assays (TaqMan),
genotypes of the following functional single nucleotide polymorphisms were determined: interleukin 1 beta (IL1B)
−511C>T,  interleukin  1  receptor  antagonist  (IL1RN)  1018T>C,  interleukin  4  (IL4)  −584C>T,  interleukin  6  (IL6)
−174G>C, interleukin 8 (IL8) −251A>T, interleukin 10 (IL10) −592C>A, interleukin 18 (IL18) 183A>G, tumor necrosis
factor (TNF) −308G>A, monocyte chemoattractant protein 1 (CCL2) −2518A>G, and RANTES (CCL5) −403G>A.
Results:  Neither  genotype  distributions  nor  allele  frequencies  of  any  of  the  investigated  polymorphisms  differed
significantly between BRVO patients and controls (p>0.05). Arterial hypertension was found to be significantly more
prevalent in BRVO patients than in controls (p<0.001). In a logistic regression analysis presence of arterial hypertension
was associated with an odds ratio of 3.33 (95% confidence interval: 2.42–4.57) for BRVO.
Conclusions: As none of the investigated gene variants was significantly more prevalent in BRVO patients than among
control subjects, our data suggest that these polymorphisms themselves are unlikely major risk factors for BRVO.
Branch  retinal  vein  occlusion  (BRVO)  is  a  vision-
threatening disease, commonly affecting patients older than
60 years. It frequently occurs at an arteriovenous crossing site,
where the retinal vein shares a common adventitial sheath with
the retinal artery [1,2]. Increased rigidity of the crossing artery
resulting from atherosclerotic disease has been suggested to
cause  compression  of  the  underlying  vein,  resulting  in
turbulent  blood  flow,  endothelial  damage,  and  thrombus
formation [3]. Consequently, arterial hypertension, elevated
plasma  homocysteine  concentrations,  and
hypercholesterolemia, all of which are known to contribute to
atherogenesis,  have  been  identified  as  BRVO  risk  factors
[4-7].
Atherosclerosis  itself  is  a  chronic  low-grade
inflammatory  disease,  which  is  characterized  by  the
recruitment of both monocytes and T lymphocytes to the site
of inflammation and a distinct pro-inflammatory TH1 cytokine
pattern  [8,9].  Animal  experiments  have  provided  some
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evidence that a lack of anti-inflammatory cytokines promotes
atherogenesis,  whereas  deficiency  of  pro-inflammatory
cytokines is associated with reduced atherosclerosis [10-12].
Importantly, cytokines and chemokines such as interleukin 1
beta (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor
necrosis factor alpha (TNF-α), and monocyte chemoattractant
protein  1  (MCP-1)  have  also  been  reported  to  affect
hemostasis, and may thus contribute to thrombus formation
[13-17].
Single nucleotide polymorphisms (SNPs) affecting the
expression of cytokines or chemokines previously implicated
in  atherogenesis  as  well  as  activation  of  the  coagulation
cascade  are  thus  potential  risk  factors  for  BRVO.
Nevertheless,  they  have  not  yet  been  investigated  among
BRVO patients. Consequently, in the present study, functional
gene  polymorphisms  encoding  the  following  cytokines  or
chemokines were chosen as candidate risk factors.
The pro-inflammatory cytokine IL-1β exerts strong pro-
atherogenic effects by enhancing expression of intercellular
adhesion molecule 1 (ICAM-1) and vascular cell adhesion
molecule  1  (VCAM-1)  on  endothelial  cells.  Furthermore,
IL-1β induces the synthesis of chemokines, such as IL-8 and
MCP-1, and thus facilitates the transendothelial migration of
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609inflammatory cells [18,19]. Additional evidence for its role in
atherosclerosis comes from an animal model showing that in
apoE-deficient  mice  a  lack  of  IL-1β  is  associated  with
decreased severity of atherosclerosis [20]. IL-1β also exerts
procoagulatory effects by increasing the expression of tissue
factor, which itself plays an essential role in the activation of
the  extrinsic  pathway  of  the  coagulation  cascade  [13].
Furthermore, increased expression of IL-1β downregulates
tissue–type plasminogen activator (t-PA), and thus impairs
fibrinolysis [21]. A gene polymorphism, characterized by a C
to  T  transition  at  position  –511  of  the  IL1B  gene  (IL1B
−511C>T, rs16944), affects the expression of IL1B. Iacoviello
and  coworkers  [22]  found  that  stimulation  with
lipopolysaccharide (LPS) produced a significant decrease in
tissue  factor  expression  as  well  as  IL-1β  release  in
mononuclear  cells  from  participants  carrying  the  −511TT
genotype  compared  to  those  homozygous  for  the  −511C
allele.
By binding to the IL-1 receptor without transmitting the
agonist signal, the interleukin 1 receptor antagonist (IL-1Ra)
counter-regulates IL-1β activity [18]. Animal models have
demonstrated  that  deficiency  of  IL-1Ra  affects  the
development of atherosclerotic lesions [23,24]. Recently, a
polymorphism  within  the  gene  encoding  IL-1Ra  (IL1RN
1018T>C,  rs4251961)  has  been  associated  with  both
decreased  IL-1Ra  production  and  increased  IL-6  and  C-
reactive protein (CRP) plasma concentrations [25].
Several studies support an important pathogenic role of
interleukin  4  (IL-4)  in  atherogenesis.  IL-4  mediates
proatherogenic pathways by both increasing the expression of
MCP-1,  IL-6,  VCAM-1,  and  by  upregulation  of  15–
lipoxygenase, which itself plays an essential role in oxidizing
low-density  lipoprotein  (LDL)  to  its  atherogenic  form
[26-29].  Furthermore,  mice  experiments  have  provided
evidence that IL-4 deficiency is associated with decreased
formation of atherosclerotic lesions [30,31]. IL-4 promotes
fibrinolysis by stimulating monocytes to produce t-PA [32].
A functional IL-4 polymorphism, which is characterized by a
C to T substitution in the promoter region of the IL4 gene (IL4
−584C>T, rs2243250), has been identified; thus far, it not
been studied among BRVO patients [33].
IL-6 is a pleiotropic, pro-inflammatory cytokine, which
is synthesized by monocytes and vascular endothelial cells
[34]. It has been shown to contribute to atherogenesis by
induction of endothelial dysfunction and enhancement of the
expression  of  adhesion  molecules  [35].  In  animal
experiments,  IL-6  has  been  observed  to  promote  the
development of early atherosclerotic lesions, thus strongly
confirming an essential role of IL-6 in atherogenesis [10].
Furthermore, IL-6 promotes coagulation by upregulating the
transcription  of  tissue  factor,  fibrinogen,  and  factor  VIII
[36-38]. Interestingly, IL-6 plasma levels have been reported
as a risk determinant for venous thrombosis [39]. In 1998,
Fishman  and  coworkers  identified  a  functional  gene
polymorphism in the promoter region of the IL6 gene, which
is characterized by a C to T substitution at position −174
(IL6−174G>C,  rs1800795).  Using  transfected  HeLa  cells,
Fishman and colleagues found higher baseline IL-6 levels in
cells with the G construct compared to those transfected with
the  C  allele.  Stimulation  with  LPS  or  IL-1  resulted  in  a
significantly increased IL-6 transcription rate among cells
carrying the G allele [40]. Another study using anti CD3/
CD28-stimulated peripheral blood lymphocytes found three
times higher IL-6 concentrations among carriers of the G
allele [41]. Interestingly, the IL6−174G>C polymorphism has
previously been suggested to affect susceptibility to retinal
artery occlusion (RAO). Its role in BRVO, however, still
remains elusive [42].
In contrast to IL-6, interleukin 10 (IL-10) is an anti-
inflammatory  TH2-associated  cytokine  that  mediates  anti-
atherogenic pathways by suppressing the synthesis of several
pro-inflammatory cytokines such as IL-1β, IL-6, interleukin
12 (IL-12), TFN-α, and interferon-gamma (IFN-γ) [43]. Its
protective role in atherogenesis has also been confirmed by
animal experiments [12]. As for hemostasis, IL-10 has been
shown  to  inhibit  LPS  induced  tissue  factor  expression  in
monocytes [44]. Gene polymorphisms are thought to account
for up to 75% of the variability of IL-10 production [45], and
increased  IL-10  expression  has  been  associated  with  the
presence of a TCATA haplotype formed by polymorphisms
at position -3575, -2763, -1082, -819, and -592 in the promoter
region  of  the  IL10  gene  [46,47].  Due  to  strong  linkage
disequilibrium, the presence of this haplotype can be fully
determined by analysis of the IL10−592C>A polymorphism
(rs1800872). The IL10−592A allele indicates the presence of
the presumed anti-inflammatory TCATA haplotype, while the
−592C allele indicates its absence. As for retinal vascular
diseases,  an  association  between  the  IL10−592C>A
polymorphism and RAO risk has been reported [48].
Animal models have also provided evidence that the pro-
inflammatory cytokine interleukin 18 (IL-18) contributes to
the development of atherosclerosis. In synergy with IL-12,
IL-18 promotes the TH1 immune response by inducing the
IFN-γ synthesis [19]. It also upregulates the synthesis of pro-
inflammatory cytokines such as IL-1β and IL-8 as well as the
expression of adhesion molecules [49]. In apoE knockout
mice,  administration  of  IL-18  has  been  associated  with
enhancement of atherosclerosis, whereas deficiency of IL-18
has been shown to reduce the extent of atherosclerosis [50,
51]. IL-18 expression has been found to be decreased among
carriers of the GCAGT haplotype formed by polymorphisms
at position -887, -105, +105, +183, and +533 in the promoter
and 5′untranslated region of the IL18 gene [52]. By analysis
of  the  IL18+183A>G  polymorphism  (rs5744292)  the
GCAGT haplotype can be identified, since this haplotype is
the only one including the +183G allele. Thus, the IL18+183G
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610allele  indicates  the  presence  of  this  haplotype,  while  the
+183A allele indicates its absence.
Overexpression  of  TNF-α,  a  potent  pro-inflammatory
cytokine mainly produced by macrophages and T cells, has
also been implicated in the pathogenesis of atherosclerosis
[19].  TNF-α  upregulates  both  the  expression  of  adhesion
molecules  (ICAM-1,  VCAM-1)  and  chemokines  such  as
MCP-1, thereby facilitating the recruitment of monocytes to
atherosclerotic lesions [53]. In apoE-deficient mice a lack of
TNF-α was observed to be associated with a reduced size of
atherosclerotic lesions [54]. TNF-α also exerts procoagulatory
effects  by  upregulating  tissue  factor  expression  and  by
inhibition of the thrombomodulin/protein C anticoagulation
pathway [14,15]. In addition, impairment of fibrinolysis is
caused by TNF-α induced t-PA downregulation [55].
Importantly, the migration of leukocytes to the site of
inflammation occurs along a gradient of various chemokines
including  MCP-1,  IL-8,  and  RANTES  (regulated  on
activation, normal T cell expressed and secreted). MCP-1
belongs to the CC family of chemokines, and its expression
TABLE 1. SEQUENCES OF PRIMERS AND PROBES FOR TAQMAN GENOTYPING ASSAYS.
Polymorphism Primer/probe Sequence
IL1B -511C>T (rs16944) forward primer GAGGCTCCTGCAATTGACAGA
reverse primer TCTCTACCTTGGGTGCTGTTCT
C probe VIC-CTGCCTCGGGAGCT-NFQ
T probe FAM-CTGCCTCAGGAGCT-NFQ
IL1RN 1018T>C (rs4251961) forward primer CCGGTGAGCCCTAAGTCTAAGATAG
reverse primer GCCCTTCAGACCTCATTTTGACA
T probe VIC-AAAATGGACCTGATGCTAT-NFQ
C probe FAM-AATGGACCTGGTGCTAT-NFQ
IL4 -584C>T (rs2243350) forward primer GACCTGTCCTTCTCAAAACACCTAA
reverse primer GGCAGAATAACAGGCAGACTCT
C probe VIC-CATTGTCCCCCAGTGCT-NFQ
T probe FAM-CATTGTTCCCCAGTGCT-NFQ
IL6 -174G>C (rs1800795) forward primer GACGACCTAAGCTGCACTTTTC
reverse primer GGGCTGATTGGAAACCTTATTAAGATTG
G probe VIC-CCTTTAGCATCGCAAGAC-NFQ
C probe FAM-CTTTAGCATGGCAAGAC-NFQ
IL10 -592C>A (rs1800872) forward primer GGTAAAGGAGCCTGGAACACATC
reverse primer GCCCTTCCATTTTACTTTCCAGAGA
C probe VIC-CCCGCCTGTCCTGTAG-NFQ
A probe FAM-CCGCCTGTACTGTAG-NFQ
IL18 +183A>G (rs5744292) forward primer AGCTGAGTGTAGTGACGCATG
reverse primer CTCCTGCCTCAGCCTCTTG
A probe VIC-CCTCAATCCCAGCTACT-NFQ
G probe FAM-CTCAATCCCGGCTACT-NFQ
TNF -308G>A (rs1800629) forward primer CCAAAAGAAATGGAGGCAATAGGTT
reverse primer GGACCCTGGAGGCTGAAC
G probe VIC-CCCGTCCCCATGCC-NFQ
A probe FAM-CCCGTCCTCATGCC-NFQ
CCL2 -2518A>G (rs1024611) forward primer GGAGGGCATCTTTTCTTGACAGA
reverse primer GGAAGGTGAAGGGTATGAATCAGAA
A probe VIC-CAGACAGCTATCACTTT-NFQ
G probe FAM-AGACAGCTGTCACTTT-NFQ
IL8 -251A>T (rs4073) Assay-on-demand
(C__11748116_10)
Predesigned assay from Applied Biosystems; primer and probe
sequences not available.
CCL5 -403G>A (rs2107538) forward primer ACTGAGTCTTCAAAGTTCCTGCTT
reverse primer GAGGACCCTCCTCAATAAAACACTTTATAAAT
G probe VIC-CATTACAGATCTTACCTCCTTT-NFQ
A probe FAM-CATTACAGATCTTATCTCCTTT-NFQ
Sequences of primers and probes for TaqMan genotyping assays are presented. FAM and VIC are names of fluorescent dyes.
NFQ is the abbreviation for non-fluorescent quencher.
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A TNF promoter polymorphism, which is caused by a G
to  A  substitution  at  position  −308  of  the  TNF  gene
(TNF-308G>A, rs1800629), has been reported to modulate
the expression of TNF-α. The presence of the TNF-308A
allele has been found to be associated with higher constitutive
and inducible TNF-α levels after LPS stimulation compared
to the −308GG genotype [56].in both endothelial cells and monocytes can be induced by
pro-inflammatory cytokines such as IL-1, IFN-γ, and TNF-α
[57]. A large body of evidence indicates that MCP-1 plays an
essential role in atherogenesis by recruiting monocytes and
macrophages to atherosclerotic lesions [58,59]. MCP-1 has
also  been  reported  to  have  a  procoagulant  function  by
inducing tissue factor expression [60]. An A to G substitution
at  position  −2518  of  the  MCP-1  gene  (CCL2−2518A>G,
rs1024611) has been noted to affect MCP-1 expression [61].
After IL-1β stimulation, peripheral blood mononuclear cells
from  individuals  carrying  the  −2518G  allele  showed  a
significantly  higher  MCP-1  synthesis  than  cells  from
individuals homozygous for the −2518A allele [61].
Endothelial secretion of IL-8, a member of the CXC
chemokine family, is induced by pro-inflammatory cytokines
such as IL-1 and TNF-α [62]. IL-8 is a potent chemoattractant
for neutrophils, and, like MCP-1, also triggers firm adhesion
of  rolling  monocytes  to  the  vascular  endothelium,  thus
contributing  to  the  development  of  atherosclerotic  lesions
[63].  Decreased  susceptibility  to  atherosclerosis  has  been
demonstrated in mice lacking the IL-8 receptor [64]. IL-8 has
also been shown to increase the expression of tissue factor in
monocytes [13]. Hull and coworkers [65] identified a common
SNP in the promoter region of the IL8 gene, which is caused
by an A to T substitution at position −251 (IL8−251A>T,
rs4073). The IL8−251T allele was found to be associated with
a  two-  to  fivefold  stronger  luciferase  expression  than  the
−251A allele, suggesting a pro-inflammatory effect in carriers
of this allele [66].
-403 (CCL5−403G>A, rs2107538) has been identified [70].
In  cells  transfected  with  the  −403A  variant,  increased
transcriptional activity has been demonstrated.
So far none of these functional gene polymorphisms has
been studied as a potential risk factor for BRVO. The purpose
of the present study was thus to investigate a hypothesized
association between the aforementioned gene polymorphisms
and the presence of BRVO.
METHODS
The present study enrolled 398 patients with BRVO (228
females and 170 males) and 355 control subjects (206 females
and 149 males). The mean age of patients was 67.1±11.0 years
(range:  37–93  years)  and  68.3±13.8  years  (range:  21–93
years) in the control group. All participants were of Caucasian
origin, living in the same geographical area and were seen at
the local Department of Ophthalmology, Medical University
of Graz. The study was approved by the Institutional Review
Board of the Medical University of Graz and followed the
principles of the Declaration of Helsinki. Prior to enrollment,
written informed consent was obtained from all participants.
Diagnosis of BRVO was made if fundus examination revealed
venous dilation and tortuosity with intraretinal hemorrhages
in a wedge-shaped region, with the apex of the wedge pointing
to an arteriovenous crossing point.
The  control  group  was  hospital-based  and  comprised
patients seen at the Department of Ophthalmology, Medical
University of Graz for reasons other than retinal vascular
occlusion, such as cataract or glaucoma surgery. All controls
underwent  a  detailed  fundus  examination.  Excluded  as
controls were patients who had a history of retinal vascular
occlusions,  deep  vein  thrombosis,  pulmonary  embolism,
myocardial infarction, or stroke.
Arterial hypertension was defined by a systolic blood
pressure  ≥140  mmHg,  a  diastolic  blood  pressure  of
≥90  mmHg,  or  the  intake  of  antihypertensive  drugs.
Participants were classified as diabetics if they were being
treated for insulin or non-insulin-dependent diabetes mellitus.
Hypercholesterolemia  was  defined  by  fasting  plasma
TABLE 2. DEMOGRAPHIC DATA OF PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION AND CONTROL SUBJECTS.
Clinical characteristics
BRVO patients
(n=398)
Control subjects
(n=355) p-value
Females 228 (57.3%) 206 (58.0%) 0.84
Mean age (years±SD) 67.1±11.0 68.3±13.8 0.18
Arterial hypertension 306 (76.9%) 183 (51.5%) <0.001
Diabetes mellitus 27 (6.8%) 24 (6.8%) 0.99
Hypercholesterolemia 310 (77.9%) 260 (73.2%) 0.14
Ever-smoker 119 (29.9%) 90 (25.4%) 0.16
Prevalence of arterial hypertension was significantly higher in branch retinal vein occlusion (BRVO) patients compared to
control subjects. Data are mean±standard deviation, or number of subjects (%).
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Finally,  RANTES,  a  member  of  the  CC  family  of
chemokines, is produced by T lymphocytes and monocytes.
As a potent chemoattractant, RANTES has been shown to
trigger monocyte arrest on dysfunctional endothelium [67].
Furthermore, RANTES is expressed by T cells in advanced
atherosclerotic lesions [68]. In a hypercholesterolemic mouse
model, administration of the CC chemokine antagonist Met-
RANTES  resulted  in  reduced  atherosclerotic  lesion  sizes
[69]. A SNP in the promoter region of the RANTES gene
(CCL5), which is caused by a G to A substitution at positioncholesterol levels above 200 mg/dl or the intake of lipid-
lowering drugs. Participants were classified as either ever
(current/previous) smokers or nonsmokers. A standardized
questionnaire was employed to obtain data on medication
intake as well as history of deep vein thrombosis, pulmonary
embolism, myocardial infarction, and stroke.
Candidate gene polymorphisms were selected using the
following criteria: association of the polymorphism with gene
expression or activity of the gene product; involvement of the
gene product in pro- or anti-inflammatory pathways; a minor
allele frequency of 5% or higher; and no data available on the
role  of  this  gene  variant  in  BRVO.  Genomic  DNA  was
isolated from whole blood by standard methods (QIA-AMP
DNA, blood mini kit, Qiagen, Vienna, Austria) and stored at
−20  °C.  Genotypes  of  the  aforedescribed  polymorphisms
were determined by 5′ exonuclease assays (TaqMan). Applied
Biosystems  Assay-by-Design  custom  service  (Applied
Biosystems,  Vienna,  Austria)  was  used  for  design  and
manufacture of primer and probe sets. Sequences of primers
and probes are presented in Table 1. Endpoint fluorescence
data were exported into Excel format and analyzed as scatter
plots. Samples were analyzed in batches, each containing 94
samples and 2 negative controls (water instead of DNA). Next,
50 samples were reanalyzed, and the results were identical for
all samples.
Statistics: SPSS for windows (release 15.0.1; SPSS, Inc.,
Chicago, IL) was used for statistical analyses. Continuous
variables were analyzed by Student’s t-test and presented as
means±SD.  Categorial  variables  were  presented  as
percentages and were compared by the χ2 test. Odds ratios and
95% confidence intervals (CI) were calculated by logistic
regression analysis, and genotypes were coded assuming an
allele dose effect (wildtype genotype=0, heterozygous carrier
TABLE 3. GENOTYPE AND ALLELE FREQUENCIES IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION AND CONTROL SUBJECTS.
Polymorphism Genotype BRVO patients Control subjects p-value
IL1B -511C>T (rs16944) CC 183 (46.0%) 162 (45.6%) 0.68
CT 184 (46.2%) 159 (44.8%)
TT 31 (7.8%) 34 (9.6%)
T allele frequency 0.309 0.32 0.66
IL1RN 1018T>C (rs4251961) TT 140 (35.2%) 145 (40.8%) 0.15
TC 210 (52.8%) 162 (45.6%)
CC 48 (12.1%) 48 (13.5%)
C allele frequency 0.384 0.363 0.4
IL4 -584C>T (rs2243250) CC 287 (72.1%) 253 (71.3%) 0.58
CT 106 (26.6%) 94 (26.5%)
TT 5 (1.3%) 8 (2.3%)
T allele frequency 0.146 0.155 0.62
IL6 -174G>C (rs1800795) GG 130 (32.7%) 115 (32.4%) 0.97
GC 197 (49.5%) 174 (49.0%)
CC 71 (17.8%) 66 (18.6%)
C allele frequency 0.426 0.431 0.84
IL10 -592C>A (rs1800872) CC 216 (54.3%) 186 (52.4%) 0.14
CA 161 (40.5%) 137 (38.6%)
AA 21 (5.3%) 32 (9.0%)
A allele frequency 0.255 0.283 0.22
IL18 +183A>G (rs5744292) AA 232 (58.3%) 204 (57.5%) 0.11
AG 154 (38.7%) 129 (36.3%)
GG 12 (3.0%) 22 (6.2%)
G allele frequency 0.224 0.244 0.36
TNF -308G>A (rs1800629) GG 277 (69.6%) 251 (70.7%) 0.95
GA 115 (28.9%) 99 (27.9%)
AA 6 (1.5%) 5 (1.4%)
A allele frequency 0.16 0.154 0.75
CCL2 -2518A>G (rs1024611) AA 225 (56.5%) 206 (58.0%) 0.48
AG 147 (36.9%) 133 (37.5%)
GG 26 (6.5%) 16 (4.5%)
G allele frequency 0.25 0.232 0.43
Genotype and allele frequencies were not significantly different between branch retinal vein occlusion (BRVO) patients and
control subjects, suggesting that these genotypes are not associated with BRVO risk.
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IL8 -251A>T (rs4073) AA 76 (19.1%) 82 (23.1%) 0.23
- AT 215 (54.0%) 171 (48.2%)
- TT 107 (26.9%) 102 (28.7%)
- T allele frequency 0.539 0.528 0.68
CCL5 -403G>A (rs2107538) GG 272 (68.3%) 235 (66.2%) 0.63
- GA 113 (28.4%) 104 (29.3%)
- AA 13 (3.3%) 16 (4.5%)
- A allele frequency 0.175 0.192 0.4of the mutated allele=1, homozygous carrier for the mutated
allele=2). A p<0.05 was considered statistically significant.
RESULTS
Clinical characteristics of both groups are shown in Table 2.
Arterial  hypertension  was  significantly  more  prevalent  in
BRVO patients than among control subjects (76.9% versus
51.5%; p<0.001). Hypercholesterolemia and ever-smoking
status were also higher among patients than in the control
group;  however  neither  characteristics  were  statistically
significant (Table 2).
Table  3  presents  genotype  distributions  and  allele
frequencies in BRVO patients and controls. Neither allele
frequencies  nor  genotype  distributions  of  any  of  the
investigated  gene  polymorphisms  were  found  to  be
significantly  different  between  patients  and  controls.
Observed  genotype  distributions  were  in  line  with  those
predicted  by  the  Hardy–Weinberg  equilibrium,  and  allele
frequencies among controls were similar to those previously
observed  among  other  Caucasian  populations  [22,25,52,
71-77]. In a logistic regression analysis, presence of BRVO
was predicted by arterial hypertension, but not by any of the
ten investigated gene polymorphisms (Table 4).
DISCUSSION
Increased rigidity of the retinal artery leading to compression
of the underlying vein at an arteriovenous crossing site has
strongly been implicated in the pathogenesis of BRVO [3].
We  hypothesized  that  BRVO  susceptibility  might  be
conferred by functional gene polymorphisms that affected the
expression of cytokines or chemokines, which themselves
have all been shown to affect atherogenesis. In addition, some
cytokines  also  exert  procoagulatory  effects  and  may  thus
affect  BRVO  risk  by  a  second  mechanism.  To  improve
biologic plausibility gene polymorphisms were only selected
as  candidate  risk  factors  when  these  polymorphisms  had
previously been associated with gene expression or activity of
the gene product, and an essential role of the gene product in
pro- or anti-inflammatory pathways had been known. Some
of  these  polymorphisms  have  been  associated  with
cardiovascular  diseases,  indicating  that  alterations  in  the
genetics of the inflammatory system may modify the risk of
these diseases [77-83].
Neither genotype distributions nor allele frequencies of
the investigated gene polymorphisms differed significantly
between BRVO patients and control subjects. The statistical
power of the present study to detect a potential association
between the investigated gene polymorphisms and BRVO
was calculated for the polymorphism with the lowest minor
allele frequency (IL4−584C>T). For this polymorphism, the
present study had a statistical power of 0.80 to detect an odds
ratio of ≥1.55, and a statistical power of 0.99 to detect an odds
ratio of ≥2.0 for carriers of the mutated allele. For all other
polymorphisms, the statistical power was equal or higher than
that of the IL4−584C>T polymorphism. Thus, our results
strongly suggest that none of these gene variants is likely a
major risk factor for BRVO.
The  expression  of  cytokines  and  chemokines  is  also
affected by factors other than gene polymorphisms [26,49,
57,62]. For example, the expression of MCP-1 can be induced
by pro-inflammatory cytokines such as IL-1 and TFN-α [57].
Thus, our finding that the investigated gene polymorphisms
were not associated with a significantly increased risk for
BRVO does not necessarily argue against a role of these
cytokines and chemokines in the pathogenesis of BRVO.
Large  prospective  studies  are  clearly  warranted  to
elucidate  whether  altered  plasma  concentrations  of  both
cytokines and chemokines are predictive for the development
of BRVO. This, however, can only be achieved by conducting
a prospective instead of a retrospective study. Yet, it is also
possible that increased expression of inflammatory mediators
may not be detected systemically in blood, but only locally in
the vascular wall.
When interpreting the data of the present study, some
limitations have to be considered. First, blood samples were
TABLE 4. LOGISTIC REGRESSION ANALYSIS OF BRANCH RETINAL VEIN OCCLUSION RISK.
Risk factor Odds ratio 95% Confidence Interval p-value
Arterial hypertension 3.33 2.42–4.57 <0.001
IL1B −511T 0.95 0.75–1.20 0.67
IL1RN 1018C 1.18 0.94–1.49 0.15
IL4 −584T 0.87 0.64–1.18 0.37
IL6 −174C 0.98 0.79–1.22 0.87
IL10 −592A 0.83 0.65–1.05 0.12
IL18 183G 0.89 0.69–1.16 0.39
TNF −308A 1 0.74–1.36 0.98
CCL2 −2518G 1.15 0.90–1.48 0.27
IL8 −251T 1.06 0.85–1.31 0.61
CCL5 −403A 0.86 0.66–1.13 0.28
Arterial hypertension, but none of the investigated gene polymorphisms, was significantly associated with branch retinal vein
occlusion (BRVO) risk.
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614obtained after the occurrence of BRVO. Thus, the present
study  is  not  suitable  to  investigate  plasma  cytokine  and
chemokine patterns. The aim of this study, however, was to
investigate  a  hypothesized  association  between  genetic
variants and BRVO risk. As genotypes do not change during
a person’s lifetime, the aforementioned limitation does not
apply to the analysis of gene polymorphisms. Second, gene
variants have been shown to vary between populations of
different  ethnic  origins.  Thus,  our  findings  may  not
necessarily apply to ethnicities other than Caucasian. Finally,
genetic studies are designed to compare allele or genotype
frequencies between case and control groups. A statistical
difference in frequencies between cases and controls suggests
that the investigated genetic variant is associated with the
disease. In the present candidate gene approach, we selected
genetic polymorphisms on the basis of prior knowledge of
gene function and allele frequencies. Thus, the candidate gene
approach has the advantage of a higher probability of true
association, which has been recognized as an important factor
influencing the outcome of association studies [84]. The main
limitation of the candidate gene approach is the usually low
number  of  polymorphisms  investigated.  Whole  genome
association  studies,  including  hundreds  of  thousands  of
polymorphisms, are now available. It is likely that results of
such  studies  will  provide  novel  candidates  for  genetic
susceptibility to BRVO.
In conclusion, as none of the investigated gene variants
was  significantly  more  prevalent  in  BRVO  patients  than
among  control  subjects,  our  data  suggest  that  these
polymorphisms are unlikely major risk factors for BRVO in
a Caucasian population.
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